Physician profile
Akeela Benson
NPI 1679998827
$8,632.94
in general payments reported to CMS, 2019-2025
21 companies · $5,780 in 2025
The $5,780 reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $298 · 2022: $407 · 2023: $1,078 · 2024: $1,070 · 2025: $5,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,825 · Travel and Lodging: $2,060 · Education: $44.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,824.60 |
| Travel and Lodging | $2,059.53 |
| Education | $44.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,828.63 | 2023-2025 | Ingrezza |
| Janssen Research & Development, LLC | $1,553.75 | 2025 | |
| Alkermes, INC. | $1,412.14 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $648.68 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $594.85 | 2022-2025 | Caplyta |
| Abbvie INC. | $470.95 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $465.21 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $462.33 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Indivior INC. | $302.41 | 2022-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $296.55 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $124.99 | 2025 | Fanapt |
| Genentech USA, INC. | $123.64 | 2021 | |
| Advanced Respiratory, INC | $93.30 | 2021 | |
| Gilead Sciences, INC. | $80.69 | 2021 | |
| Scilex Pharmaceuticals INC. | $42.38 | 2023-2024 | Ztlido |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $30.62 | 2024 | |
| Braeburn INC. | $28.29 | 2024 | Brixadi |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.43 | 2024 | |
| Exact Sciences Corporation | $20.61 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.70 | 2022 | |
| Novo Nordisk INC | $13.79 | 2024 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akeela Benson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.